Black Rock Inc. Eiger Bio Pharmaceuticals, Inc. Transaction History

Black Rock Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.21 - $0.43 $63,504 - $130,033	-302,404 Reduced 34.13%	583,730 $128,000
Q3 2023 Nov 13, 2023	SELL	$0.28 - $0.93 $14,277 - $47,421	-50,991 Reduced 5.44%	886,134 $265,000
Q2 2023 Aug 11, 2023	SELL	$0.55 - $1.26 $1.03 Million - $2.36 Million	-1,869,916 Reduced 66.62%	937,125 $655,000
Q1 2023 May 12, 2023	SELL	$0.89 - $2.52 $43,297 - $122,595	-48,649 Reduced 1.7%	2,807,041 $2.53 Million
Q4 2022 Feb 13, 2023	BUY	$1.02 - $7.48 $122,432 - $897,839	120,032 Added 4.39%	2,855,690 $3.37 Million

Q3 2022 Nov 14, 2022	SELL	$6.04 - $9.66 $127,293 - $203,584	-21,075 Reduced 0.76%	2,735,658 $20.6 Million
Q2 2022 Aug 12, 2022	BUY	$4.99 - $8.96 $1.56 Million - $2.8 Million	312,469 Added 12.78%	2,756,733 $17.4 Million
Q1 2022 May 12, 2022	SELL	$3.84 - $9.74 $110,208 - $279,538	-28,700 Reduced 1.16%	2,444,264 $20.3 Million
Q4 2021 Feb 10, 2022	SELL	$5.12 - $8.19 $6,016 - $9,623	-1,175 Reduced 0.05%	2,472,964 $12.8 Million
Q3 2021 Nov 09, 2021	SELL	$6.68 - $9.1 $13,246 - $18,045	-1,983 Reduced 0.08%	2,474,139 $16.5 Million
Q2 2021 Aug 11, 2021	BUY	$7.82 - $9.23 $19.4 Million - $22.9 Million	2,476,122 New	2,476,122 $21.1 Million

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $556M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.